References

arthyper

Артериальная гипертензия

"Arterial’naya Gipertenziya" ("Arterial Hypertension")

1607-419X2411-8524

Antihypertensive League

10.18705/1607-419X-2018-24-4-384-395

arthyper-543

Research Article

РЕДАКЦИОННАЯ СТАТЬЯ

EDITORIAL

Артериальная гипертония как кардиотоксическая реакция на противоопухолевую терапию: что мы знаем о новом виде ятрогенной гипертонии

Hypertension related to the antitumor treatment with angiogenesis inhibitors: an iatrogenic hypertension

Кобалава

Ж. Д.

Kobalava

Zh. D.

д.м.н., профессор, заведующая кафедрой пропедевтики внутренних болезней РУДН

ул. Миклухо-Маклая, д. 6, Москва, Россия, 117198

MD, PhD, DSc, Professor, Head, Department of Propedeutics of Internal Diseases

6 Miklukho-Maklay street, Moscow, 117198 Russia

Шаварова

Е. К.

Shavarova

E. K.

к.м.н., доцент кафедры внутренних болезней с курсом кардиологии и функциональной диагностики РУДН

ул. Миклухо-Маклая, д. 6, Москва, Россия, 117198

MD, PhD, Associate Professor, Department of Internal Diseases with the Course of Cardiology and Functional Diagnostics

6 Miklukho-Maklay street, Moscow, 117198 Russia

alisheva@rambler.ru

Федеральное государственное автономное образовательное учреждение высшего образования «Российский университет дружбы народов»РоссияPeoples’ Friendship University of RussiaRussian Federation

2018

26092018

244384395

2018

Кобалава Ж.Д., Шаварова Е.К.

Kobalava Z.D., Shavarova E.K.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://htn.almazovcentre.ru/jour/article/view/543

Одним из ключевых регуляторов сосудистого тонуса является фактор роста эндотелия сосудов (VEGF), способный усиливать продукцию оксида азота, мощного вазодилататора, и уменьшать сосудистое сопротивление посредством генерации новых сосудов микроциркуляторного русла. Оба эти механизма способствуют снижению артериального давления. Появление нового класса противоопухолевой терапии — ингибиторов ангиогенеза — закономерно привело к росту такой нежелательной реакции, как артериальная гипертензия (АГ). Целью данной публикации является анализ причин развития АГ, подходов к своевременной диагностике АГ и корректной оценке сердечно-сосудистого риска — как при планировании, так и на фоне терапии ингибиторами ангиогенеза, особенностям коррекции АГ у пациентов, получающих таргетную терапию.

One of the key regulators of vascular tone is the vascular endothelial growth factor (VEGF), which can enhance the production of nitric oxide, a potent vasodilator, and reduce vascular resistance by generating new vessels. Both mechanisms contribute to blood pressure decrease. The implementation of a new class of antitumor therapy — inhibitors of VEGF signaling pathway — results in the growth of cardiovascular complications such as arterial hypertension (HTN). The paper analyzes the causes of HTN development, approaches to the timely diagnosis of HTN and the correct assessment of cardiovascular risk before administration of VEGF inhibitors and during the treatment. We also review the features of the approaches of elevated blood pressure management in patients receiving targeted therapy.

кардиоонкологияартериальная гипертензиятирозинкиназные ингибиторы

cardio-oncologyhypertensiontyrosine kinase inhibitors

References1

An MM, Zou Z, Shen H, Liu P, Chen ML, Cao YB et al. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol. 2010;66(8):813–21.

Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2009;48(1):9. doi:10.1080/02841860802314720

Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9(2):117–23.

Qi WX, Lin F, Sun YJ, Tang LN, He AN, Yao Y et al. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. Cancer Chemother Pharmacol. 2013;71(2): 431–9.

Hamnvik OP, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer. 2015;121(2):311–9.

Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–30.

Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358 (19):2039–2049.

Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system. Circulation. 2011;124(15):1687–1691. doi:10.1161/CIRCULATIONAHA.110.992230

Hayman SR, Leung N, Grande JP, Garovic VD.VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep. 2012;14(4):285–94.

Zerbini G, Lorenzi M, Palini A. Tumor angiogenesis. N Engl J Med. 2008;359(7):763; author reply 764.

Carter JJ, Fretwell LV, Woolard J. Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats. FASEB J. 2017;31(3):1193–1203. doi:10.1096/fj.201600749R

Thijs AM, van Herpen CM, Sweep FC, Geurts-Moespot A, Smits P, van der Graaf WT et al. Role of endogenous vascular endothelial growth factor in endothelium-dependent vasodilation in humans. Hypertension. 2013;61(5):1060–1065. doi:10.1161/HYPERTENSIONAHA.111.00841

Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010;56(4):675–81. doi:10.1161/HYPERTENSIONAHA.109.149690

Verdonk K, Saleh L, Lankhorst S, Smilde JE, van Ingen MM, Garrelds IM et al. Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression. Hypertension. 2015;65(6):1316–1323. doi:10.1161/HYPERTENSIONAHA.115.05267

Lankhorst S, Kappers MH, van Esch JH, Smedts FM, Sleijfer S, Mathijssen RH et al. Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study. Hypertension. 2014;64(6):1282–1289. doi:10.1161/HYPERTENSIONAHA.114.04187

Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signaling and therapeutic inhibition. Cell Signal. 2007:19(10);2003–12.

Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008;19(5):927–34.

Steeghs N, Gelderblom H, Roodt JO, Christensen O, Rajagopalan P, Hovens M et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res. 2008;14(11):3470–6. doi:10.1158/1078-0432.CCR-07-5050

Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR et al. Mechanisms of hypertension associated with BAY 43–9006. J Clin Oncol. 2006;24(9):1363–9.

Touyz RM, Lang NN, Herrmann J, van den Meiracker AH, Danser AHJ. Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition. Hypertension. 2017;70(2):220–226. doi:10.1161/HYPERTENSIONAHA.117.08856

Schneider BP, Li L, Shen F, Miller KD, Radovich M, O’Neill A et al. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer. 2014;111(6):1241. doi:10.1038/bjc.2014.430

Sibertin-Blanc C, Mancini J, Fabre A, Lagarde A, Del Grande J, Levy N et al. Vascular endothelial growth factor a c.*237C > T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer. Dig Liver Dis. 2015;47(4):331. doi:10.1016/j.dld.2014.12.013

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology. Eur Heart J. 2016;37(36):2768–2801. doi:10.1093/eurheartj/ehw211

Maitland LM, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ et al. Initial assessment, surveillance and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102 (9):596–604. doi:10.1093/jnci/djq091

Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–630.

Mir O, Ropert S, Alexandre J, Goldwasser F. Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol. 2009;20(5):967–970.

Rini BI, Cohen DP, Lu D, Chen I, Hariharan S, Gore ME et al. Hypertension (HTN) as a biomarker of efficacy in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib. J Natl Cancer Inst. 2011 May 4;103(9):763–73. doi:10.1093/jnci/djr128

Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic metaanalysis. Cancer Chemother Pharmacol. 2010;66(2):357. doi:10.1007/s00280-009-1170-y

Hurwitz HI, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA et al. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist. 2013;18(3):273. doi:10.1634/theoncologist.2012-0339

Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441–2447.

Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370 (9604):2011–2019.

Maitland ML, Kasza KE, Karrison TG, Moshier K, Sit L, Black HR et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009;15(19):6250–6257. doi:10.1158/1078-0432.CCR-09-0058

Диагностика и лечение артериальной гипертензии. Российские рекомендации, четвертый пересмотр. Систем-ные гипертензии. 2010;3:5–26. [Diagnostics and management of arterial hypertension. Russian guidelines, 4th edition. Systemic Hypertension. 2010;3:5–26. In Russian].

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M et al. 2013 The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34 (28):2159–2219.

Mir O, Coriat R, Cabanes L, Ropert S, Billemont B, Alexandre J et al. An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist. 2011;16(9):1325–1332. doi:10.1634/theoncologist.2010–0002

Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med. 2008;358 (1):95–97.

Robinson ES, Matulonis UA, Ivy P, Berlin ST, Tyburski K, Penson RT et al. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol. 2010;5(3):477–483. doi:10.2215/CJN.08111109

Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49(2):186–93.

Lankhorst S, Baelde HJ, Clahsen-van Groningen MC, Smedts FM, Danser AH, van den Meiracker AH. Effect of high salt diet on blood pressure and renal damage during vascular endothelial growth factor inhibition with sunitinib. Nephrol Dial Transplant. 2016;31(6):914–921. doi:10.1093/ndt/gfv410

Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010;1(7):628–38.

Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K et al. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol. 2011;29(19):2635–44.

Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011;29(19):2645–52. doi:10.1200/JCO.2010.33.4441

Zhang D, Ma QY, Hu HT, Zhang M. Beta2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting creb, nfkappab and ap-1. Cancer Biol Ther. 2010;10(1):19–29.

Liao X, Che X, Zhao W, Zhang D, Bi T, Wang G. The betaadrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor kappa-b signaling. Oncol Rep. 2010;24(6):1669–76.

Park PG, Merryman J, Orloff M, Schuller HM. Betaadrenergic mitogenic signal transduction in peripheral lung adenocarcinoma: implications for individuals with preexisting chronic lung disease. Cancer Res. 1995;55(16):3504–8.

Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res. 2006;66(21):10357–64.

Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res. 2006;12(2):369–75.

Pasquier E, Ciccolini J, Carre M, Giacometti S, Fanciullino R,Pouchy C et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget. 2011;2(10):797–809.

The authors declare that there are no conflicts of interest present.